| Time | May 11-15, 2026 |
| Location | Boston, MA, USA |
| Company | DIMA BIOTECH |
| Booth | #823 |
Meet DIMA BIOTECH at PEGS Boston Summit 2026
DIMA BIOTECH is pleased to announce its participation in PEGS Boston Summit 2026, where we will showcase the latest advancements in Nanodisc technology platforms, multi-pass transmembrane protein research tools, and therapeutic monoclonal antibody development.
PEGS Boston Summit is a leading international event focused on protein engineering, antibody engineering, and biologics discovery. During the summit, DIMA BIOTECH will connect with global biopharmaceutical companies, research institutions, and partners to discuss key challenges and solutions for antibody discovery against complex membrane protein targets.
We are proud to share that our CEO, Dr. Donghui Ma, will be speaking on Wednesday, May 13, from 11:40 to 12:10 am, sharing the application of Nanodisc technology platforms to develop therapeutic mAbs for multi-pass transmembrane protein targets.
Talk Abstract:
Many important druggable targets are multi-pass transmembrane proteins. The key challenge is the extreme difficulty in obtaining purified functional proteins. To develop therapeutic lead mAbs on these targets, DIMA has optimized every step of antibody discovery process. In this poster presentation, we will exhibit how we integrate DIMA’s Nanodisc technologies, including SyndiscTM, PeptiNanodiscTM, Single B enrichment and DiLibraryTM Mammalian display technology platforms to develop mAbs against a challenge multi-pass transmembrane target, CLDN18.2.
Join Our Presentation At The Track: C2B: Emerging Targets for Oncology & Beyond
We will exhibit at Booth #823, showcasing our integrated research platform for drug discovery, including our Nanodisc Membrane Protein Platforms and Ready-to-Test Lead mAbs.
The location of DIMA BIOTECH’s exhibition booth
DiMProTM Nanodisc Membrane Protein Platforms
- Full-length GPCR proteins in native conformation
- Ion channel and multi-pass membrane protein solutions
- Stable and functional protein formats for drug discovery
- 700+ Nanodisc proteins, with 300+ in stock
Ready-to-Test Lead mAbs for Therapeutic Targets
- 5000+ Pre-validated IgG Sequences, 500+ Druggable Targets
- Zero Upfront, Zero Waiting, Zero Risk
- Functional Evaluation on Different Modality Platforms (CAR-T, ADC, BsAb, etc.)
- Mammalian Cell Display Based Antibody Engineering Platform for lead mAbs Optimization
Come learn more about our studies and connect with us at booth #823. We look forward to meeting you there!
Schedule a meeting with Us!Products
Resources
A case of Nanodisc Used in mAbs Development as Immunogen
Pick Out Your Gifts on Our Booth (#823)
Schedule a Meeting with Our Team
Complete the form to receive exclusive offers.
- ⚡ 24h response
- 🌍 Trusted by global researchers